We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
STI571 as a targeted therapy for CML.
- Authors
O'Dwyer, Michael E; Mauro, Michael J; Druker, Brian J
- Abstract
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder that progresses through distinct phases as the malignant clone progressively loses the capacity for terminal differentiation. It is characterized by the (9;22) translocation and resultant production of the Bcr-Abl tyrosine kinase. Bcr-Abl functions as a constitutively activated tyrosine kinase, and this kinase activity is absolutely required for the transforming function of the Bcr-Abl protein. In preclinical studies, STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, specifically inhibited the proliferation of Bcr-Abl-expressing cells in vitro and in vivo. STI571 has shown remarkable results in all phases of CML. Although responses are seen in all phases of the disease, durable responses are most common in earlier stage patients. Thus, STI571 has emerged as a paradigm for gene product targeted therapy, offering expanded treatment options for patients with CML.
- Publication
Cancer investigation, 2003, Vol 21, Issue 3, p429
- ISSN
0735-7907
- Publication type
Journal Article
- DOI
10.1081/cnv-120018235